Roche and AbbVie's Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA's Approval for Untreated Chronic Lymphocytic Leukemia
Shots:
- The approval is based on the P-III CLL14 study results assessing Venclexta + Gazyva vs Gazyva + chlorambucil in 432 patients with previously untreated CLL for 12mos.
- The P-IIICLL14 study results: rate of MRD-negativity in the bone marrow & peripheral blood (57% vs. 17% & 76% vs. 35%); reduction in PFS (67%); ORR (85% vs 71%); presented at ASCO in Jun’19
- Venclexta targets BCL-2 protein to restore the process of apoptosis- co-developed & co-commercialized by AbbVie and Roche and Gazyva is a mAb targeting CD20 to destroy B-cells both directly and together with the body's immune system. The combination receives FDA’s BT designation for previously untreated CLL with co-existing medical conditions
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com